Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis by Kuijpers, A.L.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25838
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
1References blood Pressure were measured before initiating combination treat-
m * mpnt anH nnre weeklv durine therapy. Clinical scores were evaluatedLevine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature m ent ana once w eeitiy  uui ing i
using the Psoriasis Severity Score modified according to Perkins et
al. [5].
The individual dosages, clinical efficacy and side effects o f each 
patient are summarised in table 1.
1991;351:453-456.
2 Donehower LA, Harvey MH, Slagle BL, et al: Mice deficient for p53 are
normal
1992;356:215-221.
3 McGregor JM, Yu CCW, Dubin EA, et al: Aberrant expression of p53 
tumor-suppressor protein in non-melanoma skin cancer. Br J Dermatol
1992;127:463-469.
4 Stephenson TJ, Royds J, Silcocks PB, et al: Mutant p53 oncogene expres- 
vmn in kprMtnnrantlinmii Anri cell carcinoma. Br J Dermatol
Case 1
A 58-year-old man was admitted because of a biopsy-proven pso­
riatic erythroderma. He had been treated with acitretin in a dosage of 
0.5 mg/kg/day during 12 weeks. Because of lack of clinical improve-
5 Ro YS, Cooper PN, Lee JA, et al: p53 protein expression in benign and m ent? combination therapy was started with cyclosporin A in a dosage
malignant skin tumors. Br J Dermatol 1993;128:237-241. 0 f  3 rne/ke/dav After 1 week of combined treatment, acitretin was
6 Shea CR, McNutt NS, Volenandt M, et al: Overexpression of p53 protein
1992;127:566-570.
in basal cell carcinoma of human skin. Am J Pathol 1992;141:25-29. decreased to 0.3 mg/kg/day because of a retinoid-induced dermatitis.
7 Matsumura Y, Sato M, Nishigori C, et al: High prevalence of mutations in After 6 weeks the serum creatinine level was elevated > 40% , and the 
the p53 gene in poorly differentiated squamous cell carcinomas in xero- serum cholesterol level and the blood pressure were raised. No clini­
cal improvement was achieved during 6 weeks treatment. Both thera-
8 De Rosa G, Staibano S, Barra E, etal: p53 proteinjn aggressive and non- pies were stopped and MTX was started at a dosage of 7.5 mg/week.
„ „ , „  , M - • * After 2 weeks the blood pressure and the cholesterol level had nor-
9 Szekeres G, de Giacomom P: Ki-67 and p53 expression m cutaneous . . _ . , r  , i t - * !, t. * - u. * 1 • 1 + a a malised, the serum creatinine level normalised alter 4 weeks* The ery-Bow ens disease: An immunohistochemical study of fixed-embedded tis- u ia u o w ’ v ° ^  j
derma oiementosum patients. J invest Dermatol
aggressive basal cell carcinoma, J Cutan Pathol 1993;20:429-434.
Derm throderma cleared
10 Sim CS, Slater SD, McKee PH: Mutant p53 protein is expressed in 
Bowen’s disease. Am J Dermatopathol 1992;14:195-199.
Hironobu Ura, MD, Department of Dermatology,
Tokyo University Branch Hospital, University of Tokyo,
3-28-6, Mejirodai, Bunkyo-ku, Tokyo, 112 (Japan)
Dermatology 1997;194:88-90
Failure of Combination Therapy with 
Acitretin and Cyclosporin A in 3 Patients with 
Erythrodermie Psoriasis
A.L.A. Kuijpers, R.J. van Dooren-Greebe, RC.M. van de Kerkhof
Department of Dermatology, University Hospital Nijmegen,
The Netherlands
Case 2
An 83-year-old man with a history of psoriasis during 5 years was 
admitted with an erythrodermic psoriasis, which was treated sub­
sequently with MTX during 2 weeks, prednisone during 2 weeks and 
acitretin 0.4 mg/kg/day during 3 weeks. These therapies were not 
successful. Cyclosporin A 3 mg/kg/day was combined with acitretin 
0.4 mg/kg/day. After 4 weeks of combined treatment, only minimal 
clinical improvement was observed. The patient complained o f dry 
lips and dry eyes. All serological parameters and the blood pressure 
were stable during therapy. Acitretin treatment was stopped and the 
cyclosporin A dose was raised to 5 mg/kg/day and combined with top­
ical calcipotriol. This resulted in a good clinical improvement after 
6 weeks.
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Case 3
>
A 67-year-old man suffering from psoriasis for more than 40 years 
was admitted with an erythrodermic psoriasis. The psoriasis did not 
respond to local steroids or coal tar both in combination with acitretin 
0.5 mg/kg/day during 8 months. Cyclosporin A (3 mg/kg/day) was 
started combined with acitretin 0.4 mg/kg/day. After 11 weeks of
combination therapy the serum creatinine level was raised with 90% 
Psoriatic erythroderma is a serious condition which requires a fast and the blood pressure had increased. The clinical response was un­
response to therapy, preferably during an in-patient treatment. Thera- satisfactory. Subsequently, both therapies were stopped and treatment 
peutic options include various topical treatments and photo(chemo)- with MTX 7.5 mg/week was initiated. However, 5 weeks later the
therapy, but in most cases systemic treatment is necessary [1]. Combi- patient had a cerebrovascular accident, complicated by fatal pul-
nation of cyclosporin A and methotrexate (MTX) resulted in serious monary embolism.
adverse events after a short treatment period, and therefore is not 
recommended [2], Combination o f etretinate and MTX may lead to
Considering the different modes of action and different side effect 
profiles, combination therapy of retinoids and cyclosporin A is a
increased hepatotoxic risks, by increasing the MTX plasma levels promising approach. However, because both retinoids and cyclo-
[3,4]. Because of the different mechanisms of action and a different 
side effect profile combined treatment of cyclosporin A and retinoids 
might be successful.
Three patients with psoriatic erythroderma, who did not respond
to monotherapy with acitretin in adequate dosages, were treated with normal human liver [6, 71. With
sporin A are metabolised in the liver via a cytochrome P450-depen- 
dent system, a risk for interaction resulting in increased cyclosporin A 
levels is present. Recently, the effect of etretinate on the cyclosporin A 
metabolism was studied in an in vitro assay, using microsomes from
combined therapy consisting of acitretin and cyclosporin A. They did
known
olism or with nephrotoxic potentials. Serum creatinine level, liver sporin A levels up to
10 joM  no metabolic interaction could be shown 
[6]. However, in a similar study with 100 ]iM etretinate and cyclo-
pM cyclosporin
enzymes, serum electrolyte levels, haematological parameters and by 33-45% [7], If this finding is of relevance in cyclosporin A treat-
8 8 Dermatology 1997;194:85 -91 Letters to Dermatology
Table 1. Clinical eliicacy and side effects after combined therapy with acitretin and cyclosporin A (CyA) in 3 patients with erythrodermic
»  ■
psori•’as is
Patient
I
i
3
Age
58
83
67
CyA-acitretin 
period, weeks
6
4
h
PSS = Psoriasis severity score.
CyA dose 
mg/kg/day
3
3
3
Acitretin dose 
mg/kg/day
0.3
0.4
0.4
Initial PSS
44
6 6
33
PS S at the end Side effects
55
55
33
retinoid dermatitis 
blood pressure T 
serum creatinine I 
serum cholesterol T 
dry Ups 
conjunctivitis 
dry lips 
dry nose
serum creatinine T 
blood pressure T
Table 2. Review of the literature of combined therapy with retinoids and cyclosporin A (CyA) in psoriasis
Author Patiems
n
Mean
age
years
Study
design
Diagnosis CyA dose 
mg/kg/day
Retinoid dose 
mg/kg/day
Mean
treatment
period,
weeks
Clinical
results
Side effects 
(patients affected)
retinoids CyA
Korstanje et al. 1 50 b erythrodermic 5 0.7 (E) 40 + none blood pressuret
18] psoriasis
Korstanje and 5 43 b + c plaque psoriasis 3-5 0.8 (E) 6 — dry lips (4) creatinine! (5)
van de Staak peeling
191 palms/soles (3)
alopecia(1)
a
Shah et al. |7| 1 68 b Zumbusch 1.6-3.75 0.63 (E) >30 days "h ? creatinine!
Salomon et al. 8 48 c plaque psoriasis 2 0.5 (A) 10 — retinoid none
[10| dermatitis (5)
Brechtel et al. i 64 a erythrodermic i 25-30 mg/ 38 + dry lips (2) creatininel (1)
m i psoriasis day (E) alopecia (1) blood pressure! (1)
a = Insufficient clinical response with retinoid monotherapy, introduction o f CyA; b = insufficient clinical response with CyA monotherapy, intro
duction o f  retinoid; e = tapering o f  CyA combined with introduction o f  retinoid; E = etretinate; A =  acitretin; +  =  good; ±  =  moderate; poor.
ment in which the normal trough and peak serum levels are far lower the relatively high age o f our patients, they might be more susceptible
than 30 \.\M needs further study.
The results of combination therapy in in vivo studies in patients
to the development of side effects.
Although no decisive conclusions can be drawn regarding the
with chronic plaque or erythrodermic psoriasis previously described value o f combined treatment with acitretin and cyclosporin A in ery-
in the literature are summarised in table 2 [7-11]. The efficacy of throdermic psoriasis, it proved not to be a major therapeutic force in
combination therapy in plaque psoriasis is poor [9, 10]. Frequently our patients, 
reported side effects are retinoid dermatitis and raised serum creati­
nine levels. However, the 3 patients with erythrodermic psoriasis pre­
viously reported in the literature showed a satisfactory improvement 
[8, 11]. This is in contrast with the patients described here, who 
achieved poor clinical results. Two patients showed cyclosporin A- 
induced side effects already after a short treatment period. Because of
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